The first FDA approval for a bispecific antibody in oncology was blinatumomab, which targets CD3 and CD19, in B-cell acute lymphoblastic leukemia in 2017 [135]. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.